Literature DB >> 35237434

Management of infective endocarditis in pregnancy by a multidisciplinary team: a case series.

Kayle S Shapero1, Varidhi Nauriyal2, Christina Megli3, Kathryn Berlacher1, Sami El-Dalati4.   

Abstract

INTRODUCTION: The incidence of infective endocarditis (IE) in pregnancy is rare and has been increasing during the opioid epidemic. IE in pregnancy is associated with high rates of maternal and fetal morbidity and mortality. Multidisciplinary endocarditis teams for management of IE have been shown to reduce in-hospital and 1-year mortality. We present a single-center experience managing IE in pregnancy utilizing a multidisciplinary endocarditis team.
METHODS: Patients diagnosed with IE while pregnant or within 30 days post-partum were identified. All patients discussed at the institution's weekly multidisciplinary endocarditis meeting were included. Demographic and clinical data and outcome-related variables were retrospectively reviewed and recorded.
RESULTS: Between 1 October 2020 and 1 June 2021 6 pregnant or 30-day post-partum patients with IE were identified. All patients had co-morbid injection drug use; Staphylococcus aureus was the etiologic pathogen in all patients. All patients had embolic complications and 5 required ICU admission and mechanical ventilatory support. Four patients underwent valve replacement. There were no patient-directed discharges. All patients survived to hospital discharge and 90-days after diagnosis. Four pregnancies resulted in delivery at an average gestational age of 32.4 weeks with 3 requiring NICU admissions and prolonged lengths of stay. All patients were seen by addiction medicine and 5 were started on medication-assisted treatment for opioid use disorder. DISCUSSION: In a small retrospective cases series, coordination of care by a multidisciplinary endocarditis team led to a high-rate of surgical intervention with no patient-directed discharges and no in-hospital or 90-day mortality.
CONCLUSION: Multidisciplinary endocarditis teams are a low-risk intervention that may improve outcomes in pregnant patients with IE.
© The Author(s), 2022.

Entities:  

Keywords:  endocarditis; injection drug use; multidisciplinary team; pregnancy

Year:  2022        PMID: 35237434      PMCID: PMC8883368          DOI: 10.1177/20499361221080644

Source DB:  PubMed          Journal:  Ther Adv Infect Dis        ISSN: 2049-9361


Introduction

Infectious endocarditis in pregnancy can present challenging management dilemmas. While the reported incidence is rare (0.006%), there has been an uptrend in endocarditis complicating pregnancies with the current opioid epidemic.[1 –3] The cardiovascular physiology adaptations to pregnancy confer a substantial risk of hemodynamic collapse with acute valve failure secondary to endocarditis. Maternal mortality reports have ranged from 10% to 33% with recent studies demonstrating improving outcomes, likely due to early recognition and prompt initiation of treatment.[1,3,4] Fetal mortality from maternal endocarditis in the United States may be as high as 14.6%. In addition, more than half of deliveries complicated by endocarditis are pre-term with an average gestational age of 32.4 weeks, with further morbidity associated with prematurity. While maternal outcomes from cardiac surgery are reportedly similar to non-pregnant women, current literature on management is limited to case series and retrospective reviews and data on neonatal outcomes have not been characterized.[3,6,7] Discussions regarding indications and timing of valve surgery are particularly complex given poor fetal outcomes with cardiopulmonary bypass.[6,7] Consequently, delivering effective care often requires coordination among several specialties. Multidisciplinary endocarditis teams for management of infective endocarditis have been shown to reduce in-hospital and 1-year mortality.[8,9] However, the impact of this approach on the pregnant/peripartum population has not been previously studied. We present a 1-year single-center experience managing IE in pregnancy utilizing a multidisciplinary endocarditis team.

Methods

Patient cases

Ethical approval was obtained from the University of Pittsburgh. Institutional Rreview Board (IRB #20090137). Patient consent was not required as the study was exempted by the IRB. Consecutive patients diagnosed with infectious endocarditis while pregnant or within 30-days post-partum and whose cases were discussed at the institution’s weekly multidisciplinary endocarditis meeting were enrolled. Patient management plans were finalized by the endocarditis team, comprised of faculty from the departments of cardiac surgery, cardiology, infectious diseases, neurology, psychiatry and addiction medicine with ad hoc contributions from obstetrics and gynecology. Patient data were retrospectively reviewed by a study investigator not involved in the patients’ care. Demographic, clinical and outcomes related variables were recorded.

Multidisciplinary endocarditis team

The multidisciplinary endocarditis team at the University of Pittsburgh Medical Center’s (UPMC) Presbyterian and Montefiore hospitals was initially created in September 2019. In September 2020 an infectious diseases consult service, known as the endovascular infections team (EVI), dedicated specifically to caring for patients with endocarditis and cardiac device infections was created. Primary members of the multidisciplinary endocarditis team after September 2020 included faculty from the division of infectious diseases, cardiology and addiction medicine as well as the departments of cardiac surgery, neurology and psychiatry. This group met virtually for an hour once per week on Tuesday afternoons. In addition to providing antimicrobial recommendations, the EVI service also coordinated care between the other specialties. The EVI team ensured that cardiac surgery and addiction medicine were consulted in all cases of injection drug use related endocarditis and emailed all team members as well as patients’ primary teams with the list of patients to be presented ~24 hours before the multidisciplinary endocarditis team meeting. The faculty member on service for the EVI team moderated the discussion during the meeting and helped to achieve a consensus plan from the involved providers. The multidisciplinary team made recommendations about the type and duration of antimicrobial therapy, whether such therapy could be given in the outpatient setting, the role and timing of valve surgery, the role of anticoagulation, the need for additional echocardiographic or neurologic imaging, the role and type of medication for opioid use disorder, disposition from the hospital if patients lacked a stable housing situation as well as type and interval of required specialty follow-up. At the conclusion of the meeting, an advanced practice provider working with the EVI service would document a brief note including the team’s recommendations in the patient’s electronic medical record. Pregnant patients with endocarditis were admitted to Magee Women’s Hospital at UPMC. Notably, this hospital is a separate physical building ~0.5 miles from the Presbyterian and Montefiore Hospitals where the multidisciplinary endocarditis team is based. Magee Women’s Hospital has separate infectious diseases and cardiology consult services as well as a separate echocardiography lab. In addition, Magee Women’s Hospital does not have a cardiac surgeon and the cardiac surgeons from Presbyterian and Montefiore Hospitals do not have privileges at Magee. Consulting obstetricians are available at Presbyterian and Montefiore hospitals. When a pregnant patient was found to have endocarditis, the cardiologist at Magee interpreting the echocardiogram contacted the EVI attending physician who would then add this patient to the list of patients to be discussed by the multidisciplinary endocarditis team. The EVI attending physician then notified the endocarditis team’s primary cardiac surgeon of the patient so that they could review the patient’s electronic medical record prior to the team meeting. The patient’s primary obstetrician was also invited to attend the multidisciplinary endocarditis team meeting. When discussing a pregnant patient, the multidisciplinary endocarditis team also provided guidance about timing of delivery and whether patients should be transferred from Magee Women’s Hospital to Presbyterian/Montefiore Hospital, in addition to the group’s typical recommendations (described above).

Definitions

Duration of bacteremia was defined by the number of days that elapsed between the first positive blood culture and two consecutive negative blood cultures, or a single negative blood culture if only one was obtained. Valve surgery indications were defined in accordance with American Heart Association recommendations.

Results

Demographics

Between 1 October 2020 and 1 May 2021 6 pregnant or 30-day post-partum patients with infectious endocarditis were identified. The average patient age was 29.3 years (median: 28 years, range: 26–37 years; Table 1). The average gestational age at presentation was 22.6 weeks (median: 26 weeks, range: 6–34 weeks) including 2 patients who presented in labor. No patients presented post-partum. All patients had co-morbid injection drug use and carried a mental health disorder diagnosis. Two patients had prior endocarditis, and 1 had a bicuspid aortic valve which served as additional endocarditis risk factors. Five patients presented to Magee Women’s Hospital initially and 1 patient presented to Presbyterian/Montefiore Hospitals. Four of 5 patients initially admitted to Magee were transferred to Presbyterian/Montefiore, including 3 who were immediately post-partum or post-miscarriage and subsequently underwent valve surgery.
Table 1.

Demographic data for pregnant patients with infectious endocarditis managed by the multidisciplinary endocarditis team at the University of Pittsburgh Medical Center.

VariableN (%)MeanMedianRange
Average age at delivery29.3 years28 years26–37 years
Race
 Black1 (17)
 White5 (83)
Distance from tertiary care site46 miles50 miles5–75 miles
Medicaid/Medicare6 (100)
Gestational age at first obstetrics visit10.9 weeks9.3 weeks6 – 17.5weeks
Gestational age at diagnosis22.6 weeks26 weeks6–34 weeks
Gravida-multiparous6 (100)G4G4G2 – G5
Incarceration at the time of pregnancy/prior to diagnosis1 (17)
Hypertension0 (0)
Coronary artery disease0 (0)
Chronic kidney disease0 (0)
Obesity1 (17)
Hepatitis C antibody positive5 (83)
HIV infection0 (0)
Rheumatic fever0 (0)
Thyroid disease0 (0)
Asthma0 (0)
Tobacco use3 (50)
Injection drug use6 (100)
Mental health disorder6 (100)
Bicuspid aortic valv1 (17)
Prosthetic valve0 (0)
Intracardiac devices0 (0)
Congenital heart disease0 (0)
History of endocarditis2 (33)
Medication assisted treatment of opioid use disorder3 (50)

HIV, human immunodeficiency virus.

Demographic data for pregnant patients with infectious endocarditis managed by the multidisciplinary endocarditis team at the University of Pittsburgh Medical Center. HIV, human immunodeficiency virus. Methicillin-susceptible Staphylococcal aureus (MSSA) was the etiologic pathogen in all patients (Table 2). Five patients had right-sided endocarditis. Three patients had isolated tricuspid disease and 1 had pulmonic involvement. One patient had both mitral and tricuspid valve vegetations and one patient had isolated mitral valve endocarditis. Five patients had septic pulmonary emboli on chest computerized tomography. Three patients had radiographic evidence of cerebral emboli, including two who presented clinically with stroke, one of whom suffered an intracranial hemorrhage. Five patients required intensive care unit admission and required mechanical ventilatory support. The average duration of bacteremia was 5.8 days (median: 5.5 days, range: 2–12 days). Three patients underwent uncomplicated transesophageal echocardiography as part of their diagnostic evaluation.
Table 2.

Description of endocarditis and modality of medical therapy for pregnant patients with endocarditis.

VariableN (%)MeanMedianRange
Valve location
 Tricuspid4 (67)
 Mitral2 (33)
 Pulmonic1 (17)
 No vegetation visualized
Duration of bacteremia5.8 days5.5 days2–12 days
Organism
 MSSA6 (100)
Average vegetation size1.9 x 1.2 cm1.7 x 1 cm0.5 cm x 0.7 cm to 2 cm x 2 cm
Suspected source
 Injection-drug use6 (100)
Embolic phenomenon
 Stroke3 (50)
 Pulmonic septic emboli5 (87)
 Other septic emboli3 (50)
Mechanical ventilation5 (83)
Regurgitation severity
 Mild1 (17)
 Moderate2 (33)
 Moderate-severe2 (33)
 Severe1 (17)
Heart failure1 (17)
Average ejection fraction58%55%52%–62%
Arrhythmia1 (17)
ICU admission5 (83)
Average ICU length of stay7 days7 days2–15 days
Surgical Indication
 Heart failure from valve dysfunction1 (17)
 Persistent bacteremia3 (50)
 Abscess/heart block/destructive penetrating lesion0 (0)
 Recurrent emboli despite antibiotic therapy4 (67)
 Large vegetation (>1.0–1.5 cm)5 (84)
Antimicrobial agents
 Oxacillin5 (83)
 Cefazolin1 (17)
 Combination antibiotic therapy3 (50)
 Transition to oral antibiotics1 (17)
Duration of antimicrobial treatment42 days42 days28–56 days
Successful completion of antibiotic therapy5 (83)
Addiction medicine consult6 (100)
New medication for opioid use disorder started during admission5 (83)

ICU, Intensive care unit; MSSA, Methicillin-susceptible Staphylococcus aureus.

Description of endocarditis and modality of medical therapy for pregnant patients with endocarditis. ICU, Intensive care unit; MSSA, Methicillin-susceptible Staphylococcus aureus.

Management

Four patients underwent post-partum valve replacement as part of their endocarditis treatment at an average of 17.8 days (median: 16.5 days, range: 15–21 days) after admission (Table 3). Prior to surgery two patients delivered spontaneously at 34 weeks and 39 weeks, 4 days. One patient underwent emergency C-section at 28 weeks and 1 miscarried at 10 week, 5 days. Indications for surgery in patients undergoing valve replacement included recurrent emboli in all 4 individuals, 3 of whom had vegetations  > 1.0 cm. One patient also had persistent bacteremia for 7 days. One patient underwent an isolated tricuspid valve replacement, 1 received a tricuspid valve replacement with patent foramen ovale closure, 1 underwent isolated mitral valve replacement and 1 underwent both tricuspid and mitral valve replacements. All 4 had extensive valve destruction at the time of surgery that precluded valve repair. Timing of surgery in patients with cerebral emboli was determined by the multidisciplinary endocarditis team with input from cardiac surgery, neurology, and neurosurgery. Of the 2 patients who were managed medically, both had persistent bacteremia  > 7 days, large vegetations  > 1.0 cm and 1 had accompanying heart failure secondary to severe valve dysfunction. Since both patients had desired pregnancies surgery was not performed antenatally due to the potential fetal impact of cardiopulmonary bypass.
Table 3.

Mortality, surgical and post-operative outcomes for pregnant patients with endocarditis managed by the multidisciplinary endocarditis team.

OutcomeN (%)MeanMedianRange
In hospital mortality0 (0)
90-day mortality0 (0)
Average time from admission to cardiac surgery consultation6.8 days7 days2–15 days
Surgical intervention details
 Valve replacement4 (67)17.8 days85 minutes16.5 days72 minutes12–21 days63–133 minutes
 Valve repair0 (0)
 Other (PFO closure)1 (0)
 Time from admission to intervention
 Average cardiopulmonary bypass time
CIED required1 (17)
Intracranial hemorrhage post operatively1 (17)
Average length of stay30 days28 days17–46 days
30-day readmission2 (33)

CIED, cardiac implantable electronic device; PFO, patent foramen ovale.

Mortality, surgical and post-operative outcomes for pregnant patients with endocarditis managed by the multidisciplinary endocarditis team. CIED, cardiac implantable electronic device; PFO, patent foramen ovale. After initial empiric antibiotic therapy all patients were narrowed to targeted antimicrobial treatment with an anti-staphylococcal beta-lactam. Three were treated with combination beta-lactam therapy until blood culture clearance.[11,12]

Maternal outcomes

All 6 patients survived until hospital discharge and were alive at 90-days after diagnosis. Four patients remained in the hospital to complete intravenous antibiotic therapy, including 3 who underwent valve replacement. One patient was discharged after ~4 weeks of intravenous oxacillin on oral antibiotics for an additional 2 weeks. One was transferred to another institution closer to her home after clinical stabilization. In all, 5 of 6 patients were discharged on medication for opioid use disorder. Four patients followed-up with cardiac surgery, 2 with infectious diseases and 2 with an obstetrician (Table 4). Only one patient was discharged with a form of contraception. Two patients developed recurrent endocarditis with different micro-organisms in the setting of relapsed injection drug use ~4 and 7 months post-operatively. One of these patients underwent redo mitral valve replacement and developed endocarditis again 4 months after the second operation secondary to ongoing injection drug use.
Table 4.

Post-discharge outcomes, including rates of follow-up, relapsed injection drug use and recurrent endocarditis for pregnant patients with endocarditis managed by the multidisciplinary endocarditis team.

OutcomeN (%)
Total number of follow up visits
 Emergency department visits7
 Obstetrics visits2
 Cardiology visits2
 Cardiac surgery visits4
 Infectious disease visits2
 Primary care visits8
Contraception use1 (17)
30-day readmission2 (33)
Recurrent endocarditis2 (33)
Relapsed injection drug use3 (50)

Fetal/neonatal outcomes

Four pregnancies resulted in delivery at an average gestational age of 32.4 weeks (median 31 weeks, range 28–39 weeks; Table 5). There was one miscarriage at 10 weeks, 5 days and one patient was lost to follow-up with an unknown pregnancy outcome. Three deliveries were spontaneous vaginal deliveries and 1 was an emergent c-section secondary to fetal bradycardia. Average available birthweight for 3 babies was 1816 g (median 1083 g, range 1050 – 3316 g) with APGAR scores at 1 and 5-minutes averaging 2.3 and 5.7, respectively (median 1, 7, range (1,2–5,7, Table 6). Three babies required neonatal ICU admission with an average length of stay of 44.3 days (median: 46 days, range: 17–70 days). Two infants met clinical criteria for neonatal respiratory distress syndrome and 2 suffered Grades 1–2 intraventricular hemorrhages. One baby met diagnostic criteria for neonatal abstinence syndrome. Two mothers were unable to breastfeed secondary to their ongoing medical issues. A third mother’s child resided with family members  > 60 miles from UPMC Presbyterian/Montefiore and consequently was unable to breastfeed. A fourth delivered an infant after discharge from UPMC and the authors could not ascertain whether or not she chose to breastfeed. Despite prematurity and long-term antenatal antibiotic exposure, no infants developed necrotizing enterocolitis.
Table 5.

Obstetric outcomes for pregnant patients with endocarditis managed by the multidisciplinary endocarditis team.

OutcomeN (%)MeanMedianRange
Mode of delivery
 Spontaneous vaginal delivery3 (50)
 C-section1 (17)
 Unknown1 (17)
Indication for C-sectionFetal bradycardia
Post-partum hemorrhage0 (0)
Induction of labor0 (0)
Stillbirth0 (0)
Miscarriage/IUFD1 (17)
Elective termination0 (0)
Average gestational age at birth32 weeks31 weeks28–39 weeks
Average gestational age at miscarriage10 weeks10 weeksn/a

IUFD, Intrauterine fetal demise.

Table 6.

Fetal outcomes for babies born to mothers with infectious endocarditis whose care was managed by the multidisciplinary endocarditis team.

OutcomeN (%)MeanMedianRange
Mortality1 (17)
Average Birth weight1816 g1083 g1050–3316 g
Average Apgar Scores (1, 5 minutes)(2.3, 5.7)(1, 7)(1, 2)–(5, 7)
Corticosteroids administered1 (17)
Congenital abnormalities0 (0)
Respiratory distress syndrome2 (33)
Neonatal abstinence syndrome1 (17)
Early or late onset sepsis1 (17)
Interventricular hemorrhage2 (33)
Neonatal Intensive Care Unit stay required3 (50)
Average NICU length of stay44.3 days46 days17–70 days
Breastfeeding0 (0)
Post-discharge outcomes, including rates of follow-up, relapsed injection drug use and recurrent endocarditis for pregnant patients with endocarditis managed by the multidisciplinary endocarditis team. Obstetric outcomes for pregnant patients with endocarditis managed by the multidisciplinary endocarditis team. IUFD, Intrauterine fetal demise. Fetal outcomes for babies born to mothers with infectious endocarditis whose care was managed by the multidisciplinary endocarditis team.

Discussion

In this case series we present the 1-year experience with management of infective endocarditis in pregnancy by a single center multidisciplinary team. Results are notable for an absence of maternal deaths at 90-days follow-up. This may reflect a more widespread historical trend in mortality as diagnostic capability and access to treatment for endocarditis has improved over time. While the observed mortality was low, morbidity was impacted by substantial rates of pulmonary septic emboli, stroke, ICU admission, and long lengths of stay. The epidemiologic results of our study largely reflect the national trend of IE in pregnancy, with all cases attributable to injection drug use. Despite increased rates of OUD screening and availability of treatment, data suggests that large percentages of hospitalized pregnant patients do not receive medication for opioid use disorder.[14,15] In our study, all patients were evaluated by addiction medicine and 5 were discharged on medication for opioid use disorder. We still observed a high rate of relapse and recurrent endocarditis, which is reflective of the disease course when complicated by substance use disorders. However, at the time of this study no patients had died from overdose, which may be related to the protective effects of medication for opioid use disorder. In addition, only 1 patient was discharged with contraception. It is unclear from our study how many patients were offered contraception. However, given the challenges managing endocarditis and cardiac valvular diseases in pregnancy multidisciplinary endocarditis teams may want to consider performing more detailed assessment of patients’ interest in contraception prior to hospital discharge. With respect to fetal outcomes, the series had adverse outcomes in all pregnancies, including 1 intrauterine demise. We also observed a high preterm delivery rate, with average gestational age at live birth of 32 weeks, similar to reported literature. This led to further neonatal complications with half of the neonates requiring ICU admissions and prolonged lengths of stay. There were substantial rates of low fetal birth weight, low APGAR scores, respiratory distress syndrome, and intraventricular hemorrhage. These fetal complications have been associated with adverse neurodevelopmental outcomes as well as higher disability rates in children; however, the long-term pediatric outcomes related to maternal endocarditis have not been studied.[16,17] Access to valve surgery historically has been challenging for both pregnant patients and patients who inject drugs. However, a highlight of this series was the high rate of surgical intervention which occurred in 4 patients. The use of cardiopulmonary bypass and cardiac surgery in pregnancy is still quite controversial, and data on rates of surgical intervention are limited. As discussed above, cardiac surgery was not available at Magee Women’s Hospital and the presence of the multidisciplinary endocarditis team facilitated hospital transfers and provided access to surgical opinions that would not otherwise have been readily available. Notably, all surgically managed patients in our series underwent valve surgery after delivery or miscarriage. With regards to antimicrobial treatment, 5 patients completed the recommended courses of antibiotic therapy. As a result of the multidisciplinary endocarditis team, pregnant patient with endocarditis received access to input from infectious diseases specialists with expertise in endocarditis. Consequently, 3 patients were treated with combination beta-lactam therapy, a novel approach that has been shown to decrease time to blood culture clearance and is associated with low-mortality in patients with MSSA endocarditis.[11,12] Historically patients with injection drug use and/or pregnancy have high rates of patient-directed discharges and failure of antibiotic completion.[18,19] Encouragingly, there were no patient-directed discharges after involvement of the multidisciplinary endocarditis team. While this is a small case series assessing the impact of multidisciplinary teams in caring for pregnant or post-partum patients with endocarditis, it extends existing evidence demonstrating the benefits of these teams on patient outcomes. While more robust clinical trials are needed, given the challenges conducting intervention research in both pregnant patients and individuals with endocarditis it may be difficult to obtain high quality data. In the interim, multidisciplinary endocarditis teams are a low-risk intervention that may improve outcomes in this population (Table 7).
Table 7.

Potential benefits of a multidisciplinary endocarditis team on the care of pregnant patients with endocarditis.

DisciplinePotential Benefit
Cardiac surgeryIncreased access to valve surgery
ObstetricsDecreased maternal mortality
Infectious diseasesSelection for oral antibioticsCombination antibiotic therapy
Addiction medicineIncreased access to medication for opioid use disorder
Hospital medicineDecreased patient directed discharges
Potential benefits of a multidisciplinary endocarditis team on the care of pregnant patients with endocarditis.
  19 in total

Review 1.  Cardiac operations during pregnancy: review of factors influencing fetal outcome.

Authors:  A Mahli; S Izdes; D Coskun
Journal:  Ann Thorac Surg       Date:  2000-05       Impact factor: 4.330

2.  Recent trends in treatment admissions for prescription opioid abuse during pregnancy.

Authors:  Caitlin E Martin; Nyaradzo Longinaker; Mishka Terplan
Journal:  J Subst Abuse Treat       Date:  2014-07-23

3.  Dramatic reduction in infective endocarditis-related mortality with a management-based approach.

Authors:  Elisabeth Botelho-Nevers; Franck Thuny; Jean Paul Casalta; Hervé Richet; Frédérique Gouriet; Frédéric Collart; Alberto Riberi; Gilbert Habib; Didier Raoult
Journal:  Arch Intern Med       Date:  2009-07-27

Review 4.  Prevention of bacterial endocarditis. Recommendations by the American Heart Association.

Authors:  A S Dajani; K A Taubert; W Wilson; A F Bolger; A Bayer; P Ferrieri; M H Gewitz; S T Shulman; S Nouri; J W Newburger; C Hutto; T J Pallasch; T W Gage; M E Levison; G Peter; G Zuccaro
Journal:  JAMA       Date:  1997-06-11       Impact factor: 56.272

Review 5.  Leaving the Hospital Against Medical Advice Among People Who Use Illicit Drugs: A Systematic Review.

Authors:  Lianping Ti; Lianlian Ti
Journal:  Am J Public Health       Date:  2015-10-15       Impact factor: 9.308

6.  Impact of low-grade intraventricular hemorrhage on long-term neurodevelopmental outcome in preterm infants.

Authors:  K Klebermass-Schrehof; C Czaba; M Olischar; R Fuiko; T Waldhoer; Z Rona; A Pollak; M Weninger
Journal:  Childs Nerv Syst       Date:  2012-08-23       Impact factor: 1.475

7.  Predicting Long-Term Survival Without Major Disability for Infants Born Preterm.

Authors:  Jenny Bourke; Kingsley Wong; Ravisha Srinivasjois; Gavin Pereira; Carrington C J Shepherd; Scott W White; Fiona Stanley; Helen Leonard
Journal:  J Pediatr       Date:  2019-09-04       Impact factor: 4.406

8.  Infective Endocarditis as a Complication of Intravenous Drug Use in Pregnancy: A Retrospective Case Series and Literature Review.

Authors:  Adebayo Adesomo; Veronica Gonzalez-Brown; Kara M Rood
Journal:  AJP Rep       Date:  2020-09-23

9.  Oxacillin plus ertapenem combination therapy leads to rapid blood culture clearance and positive outcomes among patients with persistent MSSA bacteraemia: a case series.

Authors:  Sami El-Dalati; Sanjay Sridaran; Marissa Uricchio; Ellen G Kline; Ryan Shields
Journal:  JAC Antimicrob Resist       Date:  2021-09-29

10.  Maternal and Fetal Outcomes Associated With Infective Endocarditis in Pregnancy.

Authors:  Michael M Dagher; Emily M Eichenberger; Kateena L Addae-Konadu; Sarah K Dotters-Katz; Celia L Kohler; Vance G Fowler; Jerome J Federspiel
Journal:  Clin Infect Dis       Date:  2021-11-02       Impact factor: 20.999

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.